Catalonia's‘ Health 2030' project aims to mobilize €2 billion to scale up its Life Sciences ecosystem in the region and transform its national health system. A central feature of this strategy is the planned National Center of Advanced Therapies in Barcelona, which will connect industry and innovative advanced therapies firms.
Following the Government's commitment to the growth of this strategic field, Barcelona-Catalonia has become a highly sought-after location for companies of all sizes to develop their R&D in Advanced Therapies, benefitting from the presence of excellent hospitals for clinical trials, efficient operative costs, and the availability of highly skilled talent. Examples include SpliceBio, which raised €50M in the most extensive Series A round for Spanish biotech, and AstraZeneca, which recently announced a record-setting investment of €800M to establish a global innovation hub in Barcelona dedicated to the development of new therapies.
The 2nd edition of the Fast-Track Program aims to offer tailored support to 20 selected Advanced Therapies companies wanting a better understanding of the current opportunities, potential collaborations, and public funding options available in Barcelona/Catalonia.